Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | DPP4 | P27487 | 16/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | FAP | Q12884 | 5/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640762 | 0.92 | DPP4 (0.60) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL5642235 | 0.90 | DPP4 (0.72) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL7148149 | 0.90 | DPP4 (0.57) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL7009156 | 0.90 | DPP4 (0.57) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL5642182 | 0.90 | DPP4 (0.57) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL5640151 | 0.90 | DPP4 (0.57) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL5643124 | 0.88 | DPP4 (0.56) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL5642738 | 0.88 | DPP4 (0.64) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL5639822 | 0.88 | DPP4 (0.55) | ALDH1A1DPP4L3MBTL1USP2TSHR | |
| SCHEMBL5640401 | 0.88 | DPP4 (0.55) | ALDH1A1DPP4L3MBTL1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | claimed |
| EP-1561752-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-08-10 | — | — | EP | claimed |
| EP-1301187-B1 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK AS (DK) | 2005-07-06 | — | — | EP | claimed |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | claimed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| EP-1561752-A1 | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2005-08-10 | — | — | EP | disclosed |
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS BENDTZ (DK) | 2004-02-19 | — | — | US | disclosed |
| EP-1301187-A2 | HETEROCYCLIC COMPOUNDS, WHICH ARE INHIBITORS OF THE ENZYME DPP-IV | NOVO NORDISK A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2002-10-31 | — | — | US | disclosed |
| WO-2002002560-A2 | PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034014-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | ALDH1A1 360/4885DPP4 1/4885L3MBTL1 1646/4885 |
| US-20020161001-A1 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP3 | ALDH1A1 360/4885DPP4 1/4885L3MBTL1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.